CYP19A1 and breast carcinoma: Entinostat (HDACi) and letrozole (AI) can restore expression of ERα and aromatase in ER− breast cancer cell lines, resulting in growth inhibition and demonstrating the efficacy of epigenetic intervention to induce endocrine therapy sensitivity85 (Fig. 4).